Harvard Bioscience Schedules Third Quarter 2024 Earnings Conference Call for November 7, 2024 at 8:00 AM ET

HBIO 10.29.2024

SERA-AI Powered Highlights
Full Press ReleaseSEC FilingsOur HBIO Tweets

About Gravity Analytica

Recent News

  • 01.22.2025 - Sidoti Small Cap Virtual Conference
  • 01.13.2025 - Harvard Bioscience, Inc. to Participate in the Sidoti Micro Cap Conference
  • 01.08.2025 - Revolutionizing Diabetes Research: How Continuous Glucose Telemetry is Shaping the Future of Translational Therapies

Recent Filings

  • 01.03.2025 - 4 Statement of changes in beneficial ownership of securities
  • 12.27.2024 - EFFECT Notice of Effectiveness

HOLLISTON, Mass., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended September 30, 2024 before the market opens on November 7, 2024, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time.

Participants who would like to join the call and ask a question must registerhere. Once registered, you will receive the dial-in numbers and a unique PIN number.

Participants who would like to join the audio-only webcast should go to our events and presentations on the investor websitehere.

Financial information presented on the call, including the earnings release and a related slide presentation, will be available on the Investor Relations section of Harvard Bioscience’s website.

About Harvard Bioscience

Harvard Bioscience, Inc. is a leading developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, pharmaceutical and therapy discovery, bio-production and preclinical testing for pharmaceutical and therapy development. Our customers range from renowned academic institutions and government laboratories to the world’s leading pharmaceutical, biotechnology and contract research organizations. With operations in the United States, Europe, and China, we sell through a combination of direct and distribution channels to customers around the world.

For more information, please visit our website atwww.harvardbioscience.com.

Company Contact:Jennifer CoteChief Financial Officer(508) 893-3120

Investors Contact:Three Part AdvisorsSandy MartinHBIO@threepa.com(214) 616-2207

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com